Edition:
United States

ProQR Therapeutics NV (PRQR.OQ)

PRQR.OQ on NASDAQ Stock Exchange Global Market

7.35USD
11:02am EDT
Change (% chg)

$-0.20 (-2.65%)
Prev Close
$7.55
Open
$7.50
Day's High
$7.50
Day's Low
$7.20
Volume
11,928
Avg. Vol
16,227
52-wk High
$7.75
52-wk Low
$2.78

Chart for

About

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates... (more)

Overall

Beta: --
Market Cap(Mil.): $112.31
Shares Outstanding(Mil.): 24.11
Dividend: --
Yield (%): --

Financials

  PRQR.OQ Industry Sector
P/E (TTM): -- 85.69 32.76
EPS (TTM): -2.03 -- --
ROI: -68.51 1.78 14.61
ROE: -75.74 3.28 16.33

BRIEF-ProQR Announces Q1 Loss Per Share Eur 0.34

* AT MARCH 31, 2018, PROQR HELD CASH AND CASH EQUIVALENTS OF €38.0 MILLION, COMPARED TO €48.1 MILLION AT DECEMBER 31, 2017 Source text for Eikon: Further company coverage:

May 09 2018

BRIEF-ProQR Provides Enrollment Update On QR-110 Clinical Trial

* PROQR PROVIDES ENROLLMENT UPDATE ON QR-110 CLINICAL TRIAL AND HIGHLIGHTS OPHTHALMOLOGY PRESENTATIONS AT ARVO

Apr 23 2018

BRIEF-Proqr Q4 Loss Per Share ‍Eur 0.39

* PROQR ANNOUNCES RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2017 AND PROVIDES BUSINESS UPDATE

Feb 28 2018

Earnings vs. Estimates